- Home
- NBB vs ZVRA Comparison
NBB vs ZVRA Comparison
Compare NBB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBB | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.5M | 499.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBB | ZVRA |
|---|---|---|
| Price | $15.96 | $8.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 73.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $84,388,000.00 |
| Revenue This Year | N/A | $333.25 |
| Revenue Next Year | N/A | $43.70 |
| P/E Ratio | ★ N/A | $15.50 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $13.67 | $6.19 |
| 52 Week High | $16.66 | $13.16 |
Technical Indicators
Market Signals| Indicator | NBB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 36.10 |
| Support Level | $15.99 | $8.12 |
| Resistance Level | $16.32 | $8.58 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.27 | 6.63 |
Price Performance
Historical ComparisonAbout NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.